Efficacy Hard To Prove In Orphan Diseases; Dyax Panel Questions Standards
Executive Summary
One central theme of the recent advisory panel review for Dyax's hereditary angioedema therapy Kalbitor (ecallantide) was awareness that the challenges of studying an orphan disease make it difficult to provide conclusive evidence for a drug candidate